格隆汇9月1日丨上海医药(601607.SH)公布，下属上海禾丰制药有限公司（简称"上药禾丰"）的盐酸维 拉帕米注射液收到国家药品监督管理局颁发的《药品补充申请批准通知书》，该药品通过仿制药质量和 疗效一致性评价。盐酸维拉帕米注射液主要用于：1．快速阵发性室上性心动过速的转复。应用维拉帕 米之前应首选抑制迷走神经的手法治疗（如Valsalva法）。2．心房扑动或心房颤动心室率的暂时控制。 心房扑动或心房颤动合并房室旁路通道（预激综合症和LGL综合症）时除外。 ...

（於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於鹽酸維拉帕米注射液通過仿製藥一致性評價的公 告》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 年 9 月 2 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先 生、王忠先生及萬鈞女士。 * 僅供識別 证券代码：601607 证券简 ...

证券代码：601607 证券简称：上海医药 编号：临 2025-080 上海医药集团股份有限公司 关于盐酸维拉帕米注射液通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（以下简称"公司"）下属上海禾丰制药 有限公司（以下简称"上药禾丰"）的盐酸维拉帕米注射液（以下简称"该药品"） 收到国家药品监督管理局（以下简称"国家药监局"）颁发的《药品补充申请批 准通知书》（通知书编号：2025B03892），该药品通过仿制药质量和疗效一致 性评价。 规格：2ml:5mg 注册分类：化学药品 申请人：上海禾丰制药有限公司 药品批准文号：国药准字 H31021343 审批结论：本品通过仿制药质量和疗效一致性评价。 二、该药品相关的信息 盐酸维拉帕米注射液主要用于：1．快速阵发性室上性心动过速的转复。应 用维拉帕米之前应首选抑制迷走神经的手法治疗（如 Valsalva 法）。2．心房扑 动或心房颤动心室率的暂时控制。心房扑动或心房颤动合并房室旁路通道（预激 综合症和 LGL 综合 ...

人民财讯9月1日电，上海医药（601607）9月1日晚间公告，近日，公司下属上海禾丰制药有限公司的盐 酸维拉帕米注射液收到国家药监局颁发的《药品补充申请批准通知书》，该药品通过仿制药质量和疗效 一致性评价。 该药品主要用于：1．快速阵发性室上性心动过速的转复。应用维拉帕米之前应首选抑制迷走神经的手 法治疗。2．心房扑动或心房颤动心室率的暂时控制。心房扑动或心房颤动合并房室旁路通道（预激综 合症和LGL综合症）时除外。 ...

Core Viewpoint - Shanghai Pharmaceuticals Group Co., Ltd. reported a steady growth in revenue and profit for the first half of 2025, driven by its innovative transformation and strong performance in both pharmaceutical manufacturing and commercial sectors [2][3]. Company Overview and Key Financial Indicators - The company achieved operating revenue of CNY 141.59 billion, a year-on-year increase of 1.56% [3]. - Total profit reached CNY 6.82 billion, reflecting a significant growth of 41.45% compared to the previous year [3]. - Net profit attributable to shareholders was CNY 4.46 billion, up 51.56% year-on-year [3]. - The company’s net assets amounted to CNY 75.10 billion, a 4.77% increase from the end of the previous year [3]. Business and Operational Highlights - The company focuses on pharmaceutical manufacturing and commercial operations, emphasizing innovation and efficiency [3][4]. - It is the second-largest pharmaceutical commercial enterprise in China, with a comprehensive distribution network covering 25 provinces [3][4]. - The company has established strategic partnerships with major domestic and international pharmaceutical manufacturers, enhancing its supply chain capabilities [3][4]. Industry Context - The biopharmaceutical industry in China is recognized as a strategic sector, crucial for national health and security, and is currently undergoing significant structural adjustments [3][4]. - Government policies are aimed at encouraging innovation, optimizing procurement rules, and improving medical insurance payments, which are expected to drive market growth [3][4]. Research and Development - The company invested CNY 1.15 billion in R&D, accounting for 9.44% of its pharmaceutical manufacturing revenue [4][5]. - A total of 56 new drug applications were accepted for clinical trials, including 44 innovative drug projects [4][5]. - The company is advancing several key projects in various therapeutic areas, including hypertension and neurodegenerative diseases [5][6]. Commercial Strategy - The company is enhancing its digital transformation and supply chain efficiency, aiming to provide integrated healthcare solutions [12][13]. - It has launched a new retail strategy that combines traditional and online sales channels, achieving significant growth in e-commerce sales [12][13]. - The company has established a comprehensive import service system, increasing its sales revenue from imported products by 11.7% [12][13]. Corporate Governance and Investor Relations - The company emphasizes long-term stable cash dividends and shareholder returns, having distributed CNY 1.37 billion in dividends for the previous year [15][16]. - It has implemented governance improvements in line with regulatory requirements, including the addition of a female independent director [16][17]. - The company maintains strong communication with investors, ensuring transparency and engagement through various channels [17][18].

| | 上海医药集团股份有限公司2025 | 年半年度报告摘要 | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 公司 A | 股代码：601607 | 公司简称：上海医药 | | | | | | | | | | | | | H 公司 股代码：02607 | | 公司简称：上海醫藥 | | | | | | | | | | | | | | 上海医药集团股份有限公司 | | | | | | | | | | | | | | | 上海医药集团股份有限公司2025 | 年半年度报告摘要 | | | | | | | | | | | | | | 第一节 重要提示 | | | | | | | | | | | | | | 展规划，投资者应当到 | http://www.sse.com.cn | http://www.hkexnews.hk 网站仔细阅读半年度报告 | | | | | | | | | | | | | 全文。 | | | | | | | | | ...

证券代码：601607 证券简称：上海医药 公告编号：临2025-079 上海医药集团股份有限公司 第八届董事会第二十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 关联/连董事杨秋华先生主动回避该议案的表决，八位非关联/连董事全部投 票同意。 表决结果：赞成 8 票，反对 0 票，弃权 0 票 特此公告。 上海医药集团股份有限公司 上海医药集团股份有限公司（以下简称"本公司"或"上海医药"）第八届 董事会第二十四次会议（以下简称"本次会议"）于 2025 年 8 月 28 日在上海市 太仓路 200 号上海医药大厦 1101 会议室以现场结合通讯方式召开。本次会议应 到董事九名，实到董事九名，符合《中华人民共和国公司法》和本公司章程关于 董事会召开法定人数的规定。本次会议由杨秋华董事长主持，监事和部分高级管 理人员列席本次会议。 二、董事会会议审议情况 表决结果：赞成 9 票，反对 0 票，弃权 0 票 本次会议审议并通过了以下议案： 本议案已提交公司第八届董事会独立董事专门会 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% compared to the market benchmark index within the next six months [6][17]. Core Insights - The company reported a revenue of 141.59 billion yuan (+1.6%) and a net profit attributable to shareholders of 4.459 billion yuan (+51.6%) for the first half of 2025. The significant net profit growth was primarily due to a one-time special gain of approximately 1.68 billion yuan from a change in accounting treatment for a joint venture [3][4]. - The commercial segment showed steady growth, with a revenue of 129.4 billion yuan (+2.2%) and a net profit of 1.79 billion yuan (+0.1%) in H1 2025. Notably, the innovative drug business achieved a revenue of 24.2 billion yuan (+22.6%) [4]. - The industrial segment's performance improved in Q2 2025, with a revenue of 12.16 billion yuan (-4.5%) and a net profit of 1.15 billion yuan (-12.3%) for H1 2025. The company is advancing multiple innovative drug pipelines, including NDA applications and clinical trials [5]. Financial Summary - The company adjusted its profit forecasts for 2025-2027, expecting net profits of 6.22 billion yuan, 4.99 billion yuan, and 5.5 billion yuan respectively, with corresponding P/E ratios of 11, 14, and 13 times [6][12]. - The financial data indicates a gross margin of 10.84% (-0.91 percentage points) and a net margin of 4.41% (+2.39 percentage points) for Q2 2025 [5][12]. - The company’s total revenue is projected to grow from 275.25 billion yuan in 2024 to 309.97 billion yuan in 2027, with a net profit forecasted to increase from 4.55 billion yuan in 2024 to 5.51 billion yuan in 2027 [7][12].

Core Insights - Shanghai Pharmaceuticals (601607.SH) reported a total operating revenue of 141.593 billion, ranking first among disclosed peers, with a year-on-year increase of 1.56% [1] - The net profit attributable to shareholders reached 4.459 billion, also ranking first among peers, reflecting a significant year-on-year increase of 51.56% [1] - The net cash flow from operating activities was 989 million, ranking fourth among peers, with a substantial year-on-year increase of 91.98% [1] Financial Metrics - The latest debt-to-asset ratio stands at 62.68%, a decrease of 0.17 percentage points from the same period last year [3] - The gross profit margin is reported at 10.55%, an increase of 0.29 percentage points from the previous quarter [3] - Return on equity (ROE) is at 5.94%, ranking fourth among peers, with a year-on-year increase of 1.73 percentage points [3] - The diluted earnings per share (EPS) is 1.20 yuan, ranking second among peers, with a year-on-year increase of 51.90% [3] - The total asset turnover ratio is 0.62 times, ranking seventh among peers [3] - The inventory turnover ratio is 3.17 times, ranking eleventh among peers [3] Shareholder Structure - The number of shareholders is 85,100, with the top five shareholders holding a total of 2.091 billion shares, accounting for 56.40% of the total share capital [3] - The top five shareholders are: 1. Shanghai Pharmaceuticals (Group) Co., Ltd. - 19.3% 2. Yunnan Baiyao Group Co., Ltd. - 17.9% 3. Shanghai Shun International Investment Co., Ltd. - 8.10% 4. Shanghai Shun (Group) Co., Ltd. - 5.98% 5. Shanghai Tandong Enterprise Consulting Service Co., Ltd. - 5.04% [3]

证券日报网讯 8月28日晚间，上海医药发布公告称，公司第八届董事会第二十四次会议审议通过了 《2025年半年度报告及摘要》等。 （文章来源：证券日报） ...